Key statistics
As of last trade Urogen Pharma Ltd (URGN:NMQ) traded at 22.05, -26.50% below its 52-week high of 30.00, set on Nov 26, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 20.67 |
|---|---|
| High | 22.34 |
| Low | 20.46 |
| Bid | 22.02 |
| Offer | 22.08 |
| Previous close | 20.60 |
| Average volume | 663.71k |
|---|---|
| Shares outstanding | 46.81m |
| Free float | 44.98m |
| P/E (TTM) | -- |
| Market cap | 964.26m USD |
| EPS (TTM) | -3.31 USD |
Data delayed at least 15 minutes, as of Feb 18 2026 18:54 GMT.
More ▼
Announcements
- UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit
- Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy
- UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference
- UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum
- UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
- UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference
- UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025
- Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026
- ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer
More ▼
